Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.
about
What's the place of immunotherapy in malignant mesothelioma treatments?Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in miceGene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosisAntitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.Unravelling the complexity of cancer-immune system interplay.Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?Colorectal cancer vaccines in clinical trials.Immune-Mediated Therapies for Liver Cancer.Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.The gene expression profile of unstimulated dendritic cells can be used as a predictor of function.Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.Cytotoxic T lymphocytes promote cytarabine-induced acute myeloid leukemia cell apoptosis via inhibiting Bcl-2 expression.Application of nanoparticles on diagnosis and therapy in gliomas.Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls.
P2860
Q33781142-6932FC7A-7C8C-4679-B00D-CFDE96B3555EQ33823499-90DD61DB-F079-42DE-B15F-637BCF66F778Q35564075-A1439EA3-645B-4B39-A81C-F1F302E0EE7EQ35837949-F967ADC8-7C8C-4C1E-8BB5-4BC23CBD1ABAQ36579336-60F83E76-DCE8-488F-955E-4E48B4C4C844Q37416204-33A69F79-F342-47C0-A622-B03BA7F70BACQ37765590-71BD67D9-8E96-4891-B1CD-E87BFBF11468Q37891875-A9FC3466-9F05-438B-A320-3BFEECAC38B0Q37892600-97B1D481-8F9B-445D-A3D3-2F228FBDFCAEQ39144327-35B341EF-4B9B-466B-8F36-9F28EB23F760Q39409268-5796FD07-87E0-4341-B192-D3450907EDD9Q39566639-080DB28F-A143-42E2-B232-22F595A30D04Q39616709-CACACB1B-486B-4A9F-A733-96115D7D7098Q41115927-18C92505-CBB8-49B4-AE3D-DCDF73996E4CQ43165459-7867A08B-AD18-46E2-B014-C21078E57C85Q48283444-EA1181A9-0709-487C-896A-33D76247408C
P2860
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination of active specific ...... py in the treatment of cancer.
@en
Combination of active specific ...... py in the treatment of cancer.
@nl
type
label
Combination of active specific ...... py in the treatment of cancer.
@en
Combination of active specific ...... py in the treatment of cancer.
@nl
prefLabel
Combination of active specific ...... py in the treatment of cancer.
@en
Combination of active specific ...... py in the treatment of cancer.
@nl
P2860
P921
P1476
Combination of active specific ...... py in the treatment of cancer.
@en
P2093
Dorothee Herlyn
Tianqian Zhang
P2860
P2888
P304
P356
10.1007/S00262-008-0598-Y
P577
2008-10-17T00:00:00Z